Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The relation between the intracellular cyclic adenosine monophosphate (cAMP) content and the electrogenic chloride secretion induced by cholera toxin was studied in secretory HT-29 cl 19A cell monolayers. Cells were treated by the mucosal addition of cholera toxin (5 micrograms/ml) for 10, 45, or 90 minutes in Ussing chambers. After 10 minutes, the mean (
SEM
) intracellular cAMP content (3.2 (0.2) pmol/mg protein) and short circuit current (Isc) (1.9 (0.3) microA.cm-2) did not differ significantly from the corresponding basal values. At 45 minutes, a significant increase in the Isc (22.2 (5.7) microA.cm-2) was accompanied by a significant elevation in cAMP (10(1.7) pmol/mgh protein). At 90 minutes, when the stimulated Isc plateaued (35.2 (5.2) microA.cm-2), the cAMP value (99.2 (23.8) pmol/mg protein) increased further. The
protein kinase C
(
PKC
) activity of the cells was not affected by cholera toxin. Treatment of cell monolayers by different concentrations of DbcAMP (10(5), 5 x 10(-5), 10(-3) M) showed that the minimal concentration of DbcAMP (serosal) which significantly increased the Isc (delta 4.5 microA.cm-2) was 10(-4) M, and that this was accompanied by an increase in cAMP of delta 6.7 pmol/mg protein: Compared with DbcAMP, cholera toxin stimulated the Isc (at 45 minutes) to a much higher degree with a comparable elevation of cAMP. It is concluded that in cl 19A cells there is a threshold value of increase in intracellular cAMP that induces chloride secretion. Cholera toxin stimulated chloride secretion can be explained predominantly by an increase in intracellular cAMP that is unrelated to
PKC
activity.
...
PMID:Relation between chloride secretion and intracellular cyclic adenosine monophosphate in a cloned human intestinal cell line HT-29 cl 19A. 820 May 55
To determine if clinically used doses of the calcium antagonist verapamil measurably alter intracellular transduction mechanisms associated with the phosphatidylinositol pathway, lymphocyte
protein kinase C
activity was determined in subjects in a drug-free state, after 1 week of verapamil treatment (120 mg three times daily) and after a second week of verapamil treatment (240 mg sustained-release preparation once daily). Nine healthy male volunteers were studied and in these subjects baseline
protein kinase C
activity (mean +/-
SEM
; 5.07 +/- 0.76 pmol/microgram protein/min) tended to decrease after 1 week (3.50 +/- 0.20 pmol/micrograms protein/min) and was significantly decreased after 2 weeks (3.14 +/- 0.27 pmol/micrograms protein/min; p < 0.05 from baseline) of verapamil treatment. These data indicate that verapamil, at usual clinical doses, decreases
protein kinase C
activity in a marker tissue, the circulating lymphocyte. If
protein kinase C
activity in this tissue is a surrogate for other verapamil target tissues, such as vascular smooth muscle and heart muscle, these findings may provide insight into the in vivo mechanism by which verapamil decreases protein synthesis, limits cell growth, and reverses cellular hypertrophy in these tissues.
...
PMID:Verapamil decreases lymphocyte protein kinase C activity in humans. 829 15
Co-expression of EP2 and EP3 subtypes of prostaglandin E2 (PGE2) receptors (R) by U937 human monocytic cells permitted comparative studies of desensitization of each subtype. Specific binding of [3H]PGE2 to membranes of U937 cells showed a Kd of 2.9 +/- 0.3 nM (mean +/-
SEM
) and a Bmax of 40.5 +/- 1.0 fmol/mg protein, and was competitively inhibited by PGE2 > or = PGE1 > PGF2 alpha > PGD2 > PGI2. EP2 R and EP3 R mRNA were detected by reverse transcription-polymerase chain reaction and Northern blots. EP3 R expression was demonstrated by inhibition of [3H]PGE2 binding with the EP1/EP3 agonist sulprostone [50% inhibitory concentration (IC50 = 3.3 +/- 0.6 nM)] and the EP3/EP2 agonist M&B 28767 (IC50 = 2.1 +/- 0.3 nM), but not with the EP1 antagonist SC-19220. EP2 R protein was identified by Western blot analysis using specific rabbit IgG antibodies to an amino-terminal peptide of the EP2 R. EP2 R transduced PGE2 stimulation of significant increases in cellular [cAMP]i [50% effective concentration (EC50 = 20 +/- 2.5 nM)], and EP3 R mediated sulprostone inhibition of forskolin elevation of [cAMP]i (IC50 = 1.3 +/- 0.4 nM). Pretreatment of U937 cells with phorbol 12-myristate 13-acetate (PMA), which activates
protein kinase C
(
PKC
), for 1 hr reduced the total number, but not the affinity, of PGE2 R by down-regulating principally EP2 R. In contrast, a 24-hr exposure to PMA, which is known to down-regulate
PKC
, suppressed both the total number and affinity of PGE2 R on U937 cells with concurrent reductions in EP2 R and EP3 R. The down-regulation of EP2 R by PMA at 1 hr was blocked by staurosporine, an inhibitor of
PKC
, whereas the down-regulation of EP3 R by PMA at 24 hr was blocked by indomethacin. Pretreatment of U937 cells with PGE2 for 1 and 24 hr reduced both the binding affinity and the total number of PGE2 R, by co-ordinate suppression of the EP2 R and EP3 R. Desensitization of EP2 R and EP3 R for 1 hr with PGE2 suppressed subsequent PGE2-evoked chemokinetic responses to PGE2, whereas selective down-regulation of EP2 R alone by PMA for 1 hr had no effects on U937 cell migration. Thus expression of each subtype of PGE2 R is regulated independently and EP3 R, but not EP2 R, transduces PGE2 effects on migration of mononuclear phagocytes.
...
PMID:Independent down-regulation of EP2 and EP3 subtypes of the prostaglandin E2 receptors on U937 human monocytic cells. 856 30
Previous reports have suggested that 1,25-dihydroxychole-calciferol regulated cellular differentiation via its effects on
protein kinase C
activity. This study examined the in vivo effects of ergocalciferol on the activity of
protein kinase C
, and whether the differentiation of crypt intestinal cells is dependent on the activation of this enzyme. Ergocalciferol in saline was injected intramuscularly into rats and the animals sacrificed 24 hr after fasting. Protein kinase C specific activity was determined from the rate of incorporation of 32p-ATP into protamine. Injections of 60 micrograms ergocalciferol/200 g of body wt, raised
protein kinase C
specific activity to 59818 +/- 4010 (
SEM
, n = 5) cpm 32p-protamine/min/mg cell protein, compared with a control of 46173 +/- 4612 (P < 0.0005). Optimal specific activities were seen within 72 hr of injection. Administration of 120 micrograms ergocalciferol/200 g of body wt, raised the concentrations of serum calcium to 9.8 and 10.4 mg/dl following the intramuscular injection by 24 and 72 hr, respectively, compared with a control of 7.7 mg/dl. Actinomycin D (intramuscular, 100 micrograms/200 g of body wt) together with ergocalciferol (120 micrograms/200 g of body wt) reduced
protein kinase C
activity by 51% 24 hr after injection. Cycloheximide blocked the activation, but when injected alone stimulated endogenous
protein kinase C
activity by 34% 24 hr injection. The study shows activation of crypt
protein kinase C
by ergocalciferol. The inhibition of activation by actinomycin D and cycloheximide suggests the involvement of both transcriptional and translational processes in this activation.
...
PMID:Ergocalciferol and cycloheximide in vivo stimulate protein kinase C of intestinal crypt cells. 862 48
Neutrophil accumulation in the lung is implicated in the pathogenesis of pulmonary emphysema and chronic bronchitis associated with cigarette smoking. To determine whether nicotine contributes to this accumulation through the prolongation of neutrophil survival, we examined the survival rates of isolated neutrophils cultured with or without nicotine. We found that nicotine prolonged neutrophil survival in a dose-dependent fashion, with a maximum effect at 10(-6) mol/L. The survival rate at 72 hours was 35.6% +/- 1.2% in medium with 10(-6) mol/L nicotine, compared with 15.5% +/- 0.5% in control medium (mean +/-
SEM
; p < 0.01), as determined by trypan blue dye exclusion. This prolongation was brought about by suppression of apoptosis, as evidenced by both transmission electron and fluorescence microscopy, and was associated with the preservation of neutrophil functions such as chemotaxis and O2- generation. The prolongation of survival caused by nicotine was abrogated by the addition of Pro-Lys-Arg-NH2, a competitive inhibitor of the specific binding of nicotine to noncholinergic receptors on neutrophils. However, the prolongation of survival caused by nicotine was not suppressed in the presence of K-252b, an inhibitor of
protein kinase C
. These findings suggest that nicotine prolongs neutrophil survival through noncholinergic nicotine receptors and new protein synthesis, without activation of
protein kinase C
.
...
PMID:Nicotine prolongs neutrophil survival by suppressing apoptosis. 863 47
Although
protein kinase C
(
PKC
) activation has been shown to inhibit Ca2+ influx in T lymphocytes, the role of
PKC
on Ca2+ sequestration or extrusion processes has not been fully explored. We examined the effect of CD3 stimulation and
PKC
activators on cytosolic Ca2+ (Ca2+i) extrusion and 45Ca2+ efflux in human leukemic Jurkat T cells. Treatment of Fura-2 loaded cells with phorbol 12-myristate 13-acetate (PMA) or thymeleatoxin (THYM) resulted in a decrease in Ca2+i both in the presence and absence of extracellular Ca2+, whereas inactive phorbol esters had no effect.
PKC
activators added at the peak of a Ca2+i transient induced by anti-CD3 mAb, ionomycin or thapsigargin (TG) stimulated the rate and extent of return of Ca2+i to basal levels by 17-53%.
PKC
stimulation of the Ca2+i decline was not enhanced by the presence of Na+, indicating that
PKC
activators increase Ca2+ pump activity rather than a Na+/Ca2+ exchange mechanism. As CD3 receptor activation enhanced the Ca2+i decline in TG-treated cells, antigen-mediated activation of phospholipase C (PLC) signaling includes enhanced Ca2+ extrusion at the plasma membrane. The effect of
PKC
activators on parameters of Ca2+i extrusion were further explored. PMA significantly increased the rate of Ca2+ extrusion in TG-treated cells from 0.28 +/- 0.02 to 0.35 +/- 0.03 s-1 (mean +/-
SEM
) and stimulated the initial rate of 45Ca2+ efflux by 69% compared to inactive phorbol ester treated cells. The effects of
PKC
activation on the Ca2+i decline were eliminated by
PKC
inhibitors,
PKC
down regulation (24 h PMA pretreatment), ATP-depletion and conditions that inhibited the Ca2+ pump. In contrast, pretreatment of cells with okadaic acid enhanced the PMA-stimulated response. We suggest that Jurkat T cells contain a
PKC
-sensitive Ca2+ extrusion mechanism likely to be the Ca2+ pump. In lymphocytes, receptor/PLC-linked
PKC
activation modulates Ca2+i not only by inhibiting Ca2+ influx but also by stimulating plasma membrane Ca2+i extrusion.
...
PMID:Protein kinase C modulates cytosolic free calcium by stimulating calcium pump activity in Jurkat T cells. 874 51
Dopamine (DA) D2 receptors which act by modulating second messenger pathways that include
protein kinase C
(
PKC
) and adenylate cyclase (AC) have been repeatedly shown to be increased in striatum from subjects with schizophrenia. Therefore it seemed possible that chronic up-regulation of DA-D2 receptors in the schizophrenic brain could result in a change in either of these two proteins. Hence we measured
PKC
and AC in striatum from 20 schizophrenic subjects and 20 non-schizophrenic subjects by quantitative autoradiography and could show no difference in the density of either
PKC
(436 +/- 35 vs. 485 +/- 29 fmol/mg tissue equivalents (TE), mean +/-
SEM
) or AC (77 +/- 9 vs. 80 +/- 7 fmol/mg TE) in the tissue from schizophrenic compared to the non-schizophrenic subjects. Thus, these data do not support the hypothesis that
PKC
or AC are changed in the schizophrenic brain.
...
PMID:Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia. 895
The influence of phenylephrine (10(-6) M) on the regulation of junctional conductance (gj) was investigated in heart-cell pairs isolated from the ventricles of adult rats. The results indicated that phenylephrine reduced gj by 45% (
SEM
, +/- 3.4; n = 20; p < 0.05) within 2 min of it's administration to the bath. The effect of phenylephrine was dose dependent and was abolished by prazosin (10(-6) M). Moreover, the activation of
protein kinase C
seems essential for the effect of phenylephrine on gj, because previous inhibition of
protein kinase C
reduced the effect of the drug. Norepinephrine (10(-6) M) or epinephrine (10(-6) M) increased gj by 56% (
SEM
, +/- 5.3; p < 0.05; n = 14) and 43.6% (
SEM
, +/- 4.1; n = 12; p < 0.05), respectively, and their effects were larger in the alpha 1-adrenergic receptor was blocked with prazosin. The results indicate that alpha-adrenergic activation reduces gj and interacts with the influence of beta-adrenergic stimulation on junctional conductance.
...
PMID:Influence of alpha-adrenergic-receptor activation on junctional conductance in heart cells: interaction with beta-adrenergic adrenergic agonists. 905 78
Epidermal growth factor (EGF) is an important proliferative signal in the gastrointestinal tract. The EGF receptor (EGFr), which transduces the mitogenic stimulus to the cell, may be regulated by a number of factors including extracellular matrix, cell-cell contact, and other peptides. As
protein kinase C
(PK-C) has been shown to phosphorylate and down-regulate the EGFr in certain tumor cell lines, we propose that PK-C, an important regulatory enzyme, modulates the phosphorylation of the EGFr in the IEC 6 rat enterocyte cell line. IEC 6 cells were cultured in dishes with Dulbecco's modified Eagle's medium, (DMEM)/5% fetal bovine serum (FBS), which was changed to DMEM/1% FBS 24 hr prior to all experiments. Cells (three dishes per group) were treated with the PK-C activating phorbol ester phorbol-12-myristate-13-acetate (PMA) (100 nM) or vehicle for 1 hr and challenged with EGF (50 ng/ml) or vehicle for 15 min. Cell lysates were then prepared. EGFr tyrosine phosphorylation was determined by immunoprecipitating the EGFr and immunoblotting with an antibody against phosphotyrosine. EGFr apparent molecular weight was assessed in the same lysates by Western blot with an anti-EGFr antibody. Blots were analyzed by computer densitometry. Data are expressed as mean +/-
SEM
; n = 3 with P value determined by t test. Exposure of cells to PMA resulted in a decrease in the EGF-stimulated EGFr phosphotyrosine content from 96 +/- 5 U in control to 66 +/- 6 U in PMA (P < 0.01). The amount of receptor did not change, 43 +/- 3 U in control vs 44 +/- 3 U in PMA (P = 0.44). Further, exposure to PMA in the absence of EGF caused a gel shift of the EGFr band consistent with a nontyrosine phosphorylation of the protein. We demonstrate that activation of PK-C results in a modification of the EGFr coincident with inhibition of EGF-stimulated receptor tyrosine kinase activity. These data support a role for PK-C in the regulation of EGFr function and hence modulation of mitogenic signals in enterocytes.
...
PMID:Protein kinase C inhibits epidermal growth factor receptor phosphorylation in enterocytes. 920 72
A role for calcium channels in the regulation of surfactant secretion is suggested by the observation that endothelin-1-stimulated surfactant secretion is inhibited by calcium channel blockers. 1,4-Dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)-phenyl]-3-pyridi ne carboxylic acid methyl ester (Bay K 8644), a dihydropyridine derivative, stimulates voltage-dependent and non-voltage-dependent calcium channels in a number of cell types. This study demonstrates that Bay K 8644 increased phosphatidylcholine (PC) secretion in isolated lung epithelial type II cells in a time- and concentration-dependent manner with an EC50 of 100 +/- 8 nM (mean +/-
SEM
, N = 6). The secretagogue effect of Bay K 8644 was independently decreased in the absence of external calcium, or in the presence of nifedipine, a calcium channel antagonist, or inhibitors of
protein kinase C
(
PKC
). Bay K 8644 increased intracellular calcium from 130 +/- 8 to 230 +/- 14 nM (N = 6, P < 0.05), an effect that was blocked by nifedipine. Bay K 8644 also increased the membrane-associated
PKC
activity in a concentration-dependent manner. In the membranes from Bay K 8644-stimulated cells, the increase in calcium-dependent
PKC
was greater than that in the calcium-independent
PKC
, suggesting preferential translocation of calcium-dependent
PKC
to the membranes. We suggest that both elevated calcium and activation of
PKC
are required for calcium agonist Bay K 8644-induced surfactant secretion in type II cells.
...
PMID:Activation of protein kinase C by 1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)-phenyl]-3-py rid ine carboxylic acid methyl ester (Bay K 8644), a calcium channel agonist, in alveolar type II cells. 921 91
<< Previous
1
2
3
4
5
6
7
Next >>